Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 08, 2015 3:22 PM ET


Company Overview of Oligomerix, Inc.

Company Overview

Oligomerix, Inc. operates as biopharmaceutical companyand develops drugs for Alzheimer’s disease and other neurodegenerative disorders. The company was founded in 2006 and is based in New York, New York.

Audubon Business and Technology Center

Columbia University Medical Center

3960 Broadway

Suite 440C

New York, NY 10032

United States

Founded in 2006





Key Executives for Oligomerix, Inc.

Chief Executive Officer and President
Chief Commercial Officer and Director
Senior Director of Chemistry
Compensation as of Fiscal Year 2015.

Oligomerix, Inc. Key Developments

Oligomerix, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM

Oligomerix, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: James Moe, Chief Executive Officer and President.

Oligomerix, Inc. Announces the Relocation of Corporate Headquarters

Oligomerix, Inc. announced the relocation of its corporate headquarters to Valhalla, NY as of January 15, 2014 and expanded lease agreement for additional laboratory space at New York Medical College.

Taconic and Oligomerix to Collaborate on Tau Mouse Model Characterization for Use in Alzheimer's Disease Research

Taconic and Oligomerix, Inc. announced a collaboration to evaluate the utility of the Taconic tau mouse model (also known as the JNPL3 mouse) as a tool for pre-clinical testing of compounds for Alzheimer's disease. Used extensively in neurodegenerative disease research, the tau mouse model is part of the Taconic Transgenic Models(TM) (TTM(TM)) portfolio of in-licensed transgenic models available off-the-shelf in typical study quantities. For years Alzheimer's disease was believed to be caused by the toxic buildup of the amyloid beta protein. Most of the therapeutic methods under development have aimed to cut amyloid levels in order to prevent or delay onset of the disease. To date, all completed Phase III drug development programs based on the amyloid hypothesis have failed to meet their clinical endpoints. Oligomerix's work focuses on an alternate hypothesis that is rapidly advancing in the scientific community: that the accumulation of the tau protein, specifically tau oligomerization, is highly correlated with Alzheimer's disease progression and therefore an appropriate target for the development of disease-modifying therapeutics. Oligomerix will test this hypothesis using Taconic's tau mouse model that carries the transgene for the human mutation of the microtubule-associated protein -- tau. The Taconic tau model has been well-characterized for behavioral and motor disturbances related to the development of neurofibrillary tangles that are pathological hallmarks of Alzheimer's disease. Oligomerix will employ Taconic's model to develop assays to detect tau oligomers and evaluate the model's utility in preclinical testing using reference compounds already screened in cell assays.

Similar Private Companies By Industry

Company Name Region
Sonexa Therapeutics, Inc. United States
RRI International, Inc. United States
Sure Medical, Inc. United States
NovaDigm Therapeutics, Inc. United States
Bennu Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Private Placement
April 3, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oligomerix, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at